This study is in progress, not accepting new patients

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

a study on COVID-19 Vaccine

Summary

Eligibility
for people ages 18-130 (full criteria)
Healthy Volunteers
healthy people welcome
Location
at UCLA
Dates
study started
estimated completion

Description

Summary

The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.

Official Title

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19

Details

The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no specific treatments available against COVID-19 and accelerated vaccine development is urgently needed. A safe and effective vaccine for COVID-19 prevention would have significant public health impact.

Keywords

COVID-19, SARS-CoV-2, COVID-19 Vaccine, AZD1222

Eligibility

You can join if…

Open to people ages 18-130

  • Increased risk of SARS-CoV-2 infection
  • Medically stable

You CAN'T join if...

  • confirmed or suspected immunosuppressive or immunodeficient state
  • significant disease, disorder, or finding
  • Prior or concomitant vaccine therapy for COVID-19

Locations

  • Research Site
    Los Angeles California 90095 United States
  • Research Site
    San Francisco California 94102 United States
  • Research Site
    San Francisco California 94158 United States
  • Research Site
    San Diego California 92103 United States
  • Research Site
    San Diego California 92134 United States
  • Research Site
    Berkeley California 94705 United States
  • Research Site
    Los Angeles California 90033 United States
  • Research Site
    Torrance California 90502 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AstraZeneca
Links
Statistical Analysis Plan (SAP) D8110C00001-CSP-amendment-6_Redacted.pdf CSR Synopsis
ID
NCT04516746
Phase
Phase 3 research study
Study Type
Interventional
Participants
About 32459 people participating
Last Updated